我要投票 伊普诺康在医疗器械行业中的票数:236
· 外 推 电 报 ·
2025-05-09 17:26:41 星期五

【伊普诺康是哪个国家的品牌?】

伊普诺康是什么牌子?「伊普诺康」是 安徽伊普诺康生物技术股份有限公司 旗下著名品牌。该品牌发源于安徽省合肥市,由创始人蔡晓辉在2012-03-06期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力伊普诺康品牌出海!将品牌入驻外推网,定制伊普诺康品牌推广信息,可以显著提高伊普诺康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

【伊普诺康】是体外诊断行业内一家集研发、生产、销售和医学检验服务为一体的技术企业。公司创立之初,就确立了“以用户实际需求为导向”的产品理念。公司建立了新产品立项体系和完善的产品质量控制体系。

为切实贯彻公司产品理念,公司研发中心依托研发人才,搭建了包括常规生化试剂研发平台、免疫增强比浊试剂研发平台、特定蛋白分析仪及其试剂研发平台、尿生化试剂研发平台在内的多个研发平台;组建了系统参考部进行溯源研究,并报名参加IFCC举办的RELA测试,提升产品质量和溯源能力;成立了关键原材料研发中心,从源头把好质量关。

公司现有注册生化试剂产品近100项,涵盖肝功能、肾功能、心肌标志物、血脂、糖代谢、特种蛋白、肿瘤等品类,其中特色项目20余项,如小而密低密度脂蛋白胆固醇(sdLDL-C)、补体C1q、血清淀粉样蛋白A(SAA)、25羟基维生素D(25-OHD)、脂联素(ADP)、特异性生长因子(TSGF)、甘胆酸(CG)、IV型胶原蛋白(COL IV)等,此外,在注册产品达数十项。

公司自主研发的特定蛋白分析仪(梦T200 Plus)将于2019年上市,该特定蛋白分析仪能有效满足各级医院的个性化需求。该产品的成功推出,标志着伊普诺康已由过去单纯的试剂生产厂家发展为试剂和仪器配套生产的综合性生产企业。

“行远必自逊,追求无止境”。2016年2月,公司完成“新三板”挂牌(股票代码:835852),并与多家投资机构建立了战略合作关系,为公司的发展不断注入新的动力。


英文翻译:[iprnocon] is a technology enterprise integrating R & D, production, sales and medical testing services in the field of in vitro diagnosis. At the beginning of its establishment, the company established the product concept of "taking the actual needs of users as the guide". The company has established a new product project approval system and a perfect product quality control system. In order to effectively implement the company's product concept, the R & D center of the company has built a number of R & D platforms, including the R & D platform of conventional biochemical reagents, the R & D platform of immune enhancement turbidimetric reagents, the R & D platform of specific protein analyzer and its reagents, and the R & D platform of urine biochemical reagents, relying on R & D talents; established a system reference department for traceability research, and signed up to participate in the rela test held by IFCC Try to improve the product quality and traceability; set up the key raw material R & D center to control the quality from the source. The company has nearly 100 registered biochemical reagent products, covering liver function, kidney function, cardiac muscle marker, blood lipid, sugar metabolism, special protein, tumor and other categories, including more than 20 featured items, such as small and dense low-density lipoprotein cholesterol (sdldl-c), complement C1q, serum amyloid A (SAA), 25 hydroxyvitamin D (25-OHD), adiponectin (ADP), and specific growth Factor (TSGF), glycocholic acid (CG), collagen IV (coliv), etc. in addition, there are dozens of registered products. The company's self-developed specific protein analyzer (dreamt200plus) will be launched in 2019, which can effectively meet the personalized needs of hospitals at all levels. The successful launch of this product marks that iprnocon has developed from a simple reagent manufacturer to a comprehensive manufacturer of reagents and instruments. "If you go far, you will be inferior to yourself, and you will pursue endlessly.". In February 2016, the company completed the listing of the "new third board" (Stock Code: 835852), and established strategic cooperation relations with a number of investment institutions, which continuously injected new impetus into the development of the company.

本文链接: https://www.waitui.com/brand/39e768d86.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

美图旗下Wink全球月活跃用户数突破3000万

36氪获悉,美图公司数据显示,截至2024年12月31日,Wink全球月活跃用户数突破约3000万,成长为美图产品矩阵中仅次于美图秀秀和美颜相机的第三大应用。据介绍,Wink月活跃用户数环比大幅增长,持续霸榜泰国、越南、柬埔寨等东南亚多个国家的应用市场榜单第一。

2小时前

外国银行抛售印度国债创纪录,印巴冲突影响投资者信心

外国银行周四卖出了创纪录数量的印度国债,印度与巴基斯坦持续的边境冲突影响了投资者的情绪。外国银行净卖出1063亿卢比(12亿美元)的印度国债,根据印度清算公司自2006年以来的数据,这一数字创下了新高。(新浪财经)

2小时前

“降息潮”延续,存款利率全面迈向“1时代”

今年以来,存款利率下调的趋势还在不断延续。自4月以来,已有超20家商业银行下调了定期存款挂牌利率。调整后,利率3%以上的“高息存款”在市场上已经难觅踪影,银行存款利率已全面向“1时代”迈进。(金融时报)

2小时前

英伟达开源多个代码大模型,以阿里通义千问为底座

英伟达近日开源其代码推理模型(Open Code Reasoning model),包括32B、14B和7B三个参数。该模型以阿里通义千问Qwen2.5-32B、Qwen2.5-14B、Qwen2.5-7B为底座模型。(财联社)

2小时前

红塔证券:董事长提议以1亿元-2亿元回购股份

36氪获悉,红塔证券公告,公司董事长景峰提议以自有资金通过上海证券交易所交易系统以集中竞价方式回购公司部分股份,回购的股份将用于减少公司注册资本。回购资金总额不低于人民币1亿元(含),不超过2亿元(含)。回购期限自股东会审议通过回购股份方案之日起12个月内。

2小时前

本页详细列出关于伊普诺康的品牌信息,含品牌所属公司介绍,伊普诺康所处行业的品牌地位及优势。
咨询